Sunitinib Newbury 50 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sunitinib newbury 50 mg kapsel, hård

newbury pharmaceuticals ab - sunitinibmalat - kapsel, hård - 50 mg - sunitinibmalat 66,8 mg aktiv substans; propylenglykol hjälpämne; mannitol hjälpämne

Sunitinib Newbury 12,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sunitinib newbury 12,5 mg kapsel, hård

newbury pharmaceuticals ab - sunitinibmalat - kapsel, hård - 12,5 mg - mannitol hjälpämne; sunitinibmalat 16,7 mg aktiv substans; propylenglykol hjälpämne

Sunitinib Newbury 37,5 mg Kapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sunitinib newbury 37,5 mg kapsel, hård

newbury pharmaceuticals ab - sunitinibmalat - kapsel, hård - 37,5 mg - sunitinibmalat 50,1 mg aktiv substans; tartrazin hjälpämne; propylenglykol hjälpämne; mannitol hjälpämne; para-orange hjälpämne

Teriflunomide Newbury 14 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

teriflunomide newbury 14 mg filmdragerad tablett

newbury pharmaceuticals ab - teriflunomid - filmdragerad tablett - 14 mg - laktosmonohydrat hjälpämne; teriflunomid 14 mg aktiv substans

Dimethyl fumarate Newbury 240 mg Enterokapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dimethyl fumarate newbury 240 mg enterokapsel, hård

newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 240 mg - dimetylfumarat 240 mg aktiv substans; propylenglykol hjälpämne

Dimethyl fumarate Newbury 120 mg Enterokapsel, hård Sverige - svenska - Läkemedelsverket (Medical Products Agency)

dimethyl fumarate newbury 120 mg enterokapsel, hård

newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 120 mg - dimetylfumarat 120 mg aktiv substans; propylenglykol hjälpämne

Fampridine Newbury 10 mg Depottablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

fampridine newbury 10 mg depottablett

newbury pharmaceuticals ab - fampridin - depottablett - 10 mg - fampridin 10 mg aktiv substans

Icatibant Newbury 30 mg Injektionsvätska, lösning i förfylld spruta Sverige - svenska - Läkemedelsverket (Medical Products Agency)

icatibant newbury 30 mg injektionsvätska, lösning i förfylld spruta

newbury pharmaceuticals ab - ikatibantacetat - injektionsvätska, lösning i förfylld spruta - 30 mg - ikatibantacetat aktiv substans

BindRen Europeiska unionen - svenska - EMA (European Medicines Agency)

bindren

mitsubishi pharma europe ltd - colestilan - hyperfosfatemi - läkemedel för behandling av hyperkalemi och hyperfosfatemi - behandling av hyperfosfatemi hos vuxna patienter med kronisk njursjukdom stadium 5 som får hemodialys eller peritonealdialys.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Europeiska unionen - svenska - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrelhydroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotiska medel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.